STAAR Surgical Company (STAA)

NASDAQ: STAA · IEX Real-Time Price · USD
103.78
-1.13 (-1.08%)
Aug 16, 2022 11:43 AM EDT - Market open
-1.08%
Market Cap 4.96B
Revenue (ttm) 261.65M
Net Income (ttm) 33.58M
Shares Out 47.81M
EPS (ttm) 0.69
PE Ratio 150.40
Forward PE 126.58
Dividend n/a
Ex-Dividend Date n/a
Volume 136,191
Open 104.35
Previous Close 104.91
Day's Range 102.05 - 105.76
52-Week Range 49.03 - 163.08
Beta 1.08
Analysts Buy
Price Target 103.02 (-0.7%)
Earnings Date Aug 10, 2022

About STAA

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the compan... [Read more...]

Industry Health Care Equipment & Supplies
Founded 1982
CEO Caren Mason
Employees 692
Stock Exchange NASDAQ
Ticker Symbol STAA
Full Company Profile

Financial Performance

In 2021, STAA's revenue was $230.47 million, an increase of 41.00% compared to the previous year's $163.46 million. Earnings were $24.50 million, an increase of 314.36%.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for STAA stock is "Buy." The 12-month stock price forecast is 103.02, which is a decrease of -0.73% from the latest price.

Price Target
$103.02
(-0.73% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Why STAAR Surgical Stock Is Triumphant Today

Its latest earnings update shows that its products are in hot demand worldwide.

Staar Surgical (STAA) Q2 Earnings and Revenues Beat Estimates

Staar Surgical (STAA) delivered earnings and revenue surprises of 68% and 1.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Leading Medical Stock Staar Surgical Jumps After Nabbing A Second-Quarter Beat

Staar Surgical reported better-than-expected second-quarter metrics, leading STAA stock to rise moderately late Wednesday. The post Leading Medical Stock Staar Surgical Jumps After Nabbing A Second-Quar...

STAAR Surgical and Joe Jonas Team Up to Introduce New Life-Changing EVO ICL to Millions of Americans Suffering from D...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announ...

STAAR Surgical Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today report...

3 Winning Evergreen Stocks to Buy and Hold for the Next 25 Years

These companies have cornered the right markets and are chasing the right long-term trends.

Other symbols: AAPLVRTX

STAAR Surgical to Report Second Quarter Results on August 10, 2022

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announ...

Here is Why Growth Investors Should Buy Staar Surgical (STAA) Now

Staar Surgical (STAA) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Wall Street Analysts See a 42% Upside in Staar Surgical (STAA): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 41.5% in Staar Surgical (STAA). While the effectiveness of this highly sought-after metric is questionable, the p...

Should You Buy Stocks When the Market Crashes?

If you can do it and still sleep at night, then yes.

3 Reasons Why Growth Investors Shouldn't Overlook Staar Surgical (STAA)

Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.

Wall Street Analysts See a 47% Upside in Staar Surgical (STAA): Can the Stock Really Move This High?

The consensus price target hints at a 47.1% upside potential for Staar Surgical (STAA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti...

STAAR Surgical Celebrates Two Million Lens Milestone for Implantable Collamer® Lens (ICL)

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announ...

The 10 Best High-Growth Stocks to Buy

Except for energy stocks, 2022 has been a very difficult year to find any equities able to perform well in these volatile markets. And high-growth stocks have been hit especially hard.

Wall Street Analysts Think Staar Surgical (STAA) Could Surge 76%: Read This Before Placing a Bet

The consensus price target hints at a 75.9% upside potential for Staar Surgical (STAA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti...

3 Reasons Growth Investors Will Love Staar Surgical (STAA)

Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.

Staar Surgical (STAA) Q1 Earnings and Revenues Beat Estimates

Staar Surgical (STAA) delivered earnings and revenue surprises of 81.25% and 5.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

STAAR Surgical Reports Record First Quarter Net Sales of $63.2 Million Up 25% Y/Y

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today report...

After Falling More Than 56% in a Year, Is STAAR Surgical Doomed?

The stock price isn't tightly connected to its fundamentals.

Why STAAR Surgical Stock Dropped 12% This Week

Concerns about a potential drop in consumer spending may have hurt the stock.

STAAR Surgical to Report First Quarter Results on May 4, 2022

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announ...

STAAR Surgical Announces First Implants of EVO Visian ICL in the U.S.

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announ...

STAAR Surgical Surged Today: Is the Stock a Buy Now?

The company should have brighter days ahead with the FDA approval of the EVO implantable lens.

Why STAAR Surgical's Shares Are Gaining Today

The FDA approved STAAR Surgical Company's (NASDAQ: STAA) EVO/EVO+ Visian Implantable Collamer Lens to correct myopia and myopia with astigmatism. Myopia, also known as nearsightedness or the need for di...

Why STAAR Surgical Stock Is Surging Today

The FDA approved the company's EVO implantable lens for nearsightedness.